Cargando…

Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis

BACKGROUND: Abnormal glucose and lipids levels may impact survival after breast cancer (BC) diagnosis, but their association to other causes of mortality such as cardiovascular (CV) disease may result in a competing risk problem. METHODS: We assessed serum glucose, triglycerides (TG) and total chole...

Descripción completa

Detalles Bibliográficos
Autores principales: Wulaningsih, Wahyu, Vahdaninia, Mariam, Rowley, Mark, Holmberg, Lars, Garmo, Hans, Malmstrom, Håkan, Lambe, Mats, Hammar, Niklas, Walldius, Göran, Jungner, Ingmar, Coolen, Anthonius C., Van Hemelrijck, Mieke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650114/
https://www.ncbi.nlm.nih.gov/pubmed/26577580
http://dx.doi.org/10.1186/s12885-015-1928-z
_version_ 1782401449671524352
author Wulaningsih, Wahyu
Vahdaninia, Mariam
Rowley, Mark
Holmberg, Lars
Garmo, Hans
Malmstrom, Håkan
Lambe, Mats
Hammar, Niklas
Walldius, Göran
Jungner, Ingmar
Coolen, Anthonius C.
Van Hemelrijck, Mieke
author_facet Wulaningsih, Wahyu
Vahdaninia, Mariam
Rowley, Mark
Holmberg, Lars
Garmo, Hans
Malmstrom, Håkan
Lambe, Mats
Hammar, Niklas
Walldius, Göran
Jungner, Ingmar
Coolen, Anthonius C.
Van Hemelrijck, Mieke
author_sort Wulaningsih, Wahyu
collection PubMed
description BACKGROUND: Abnormal glucose and lipids levels may impact survival after breast cancer (BC) diagnosis, but their association to other causes of mortality such as cardiovascular (CV) disease may result in a competing risk problem. METHODS: We assessed serum glucose, triglycerides (TG) and total cholesterol (TC) measured prospectively 3 months to 3 years before diagnosis in 1798 Swedish women diagnosed with any type of BC between 1985 and 1999. In addition to using Cox regression, we employed latent class proportional hazards models to capture any heterogeneity of associations between these markers and BC death. The latter method was extended to include the primary outcome (BC death) and competing outcomes (CV death and death from other causes), allowing latent class-specific hazard estimation for cause-specific deaths. RESULTS: A lack of association between prediagnostic glucose, TG or TC with BC death was observed with Cox regression. With latent class proportional hazards model, two latent classes (Class I and II) were suggested. Class I, comprising the majority (81.5 %) of BC patients, had an increased risk of BC death following higher TG levels (HR: 1.87, 95 % CI: 1.01–3.45 for every log TG increase). Lower overall survival was observed in Class II, but no association for BC death was found. On the other hand, TC positively corresponded to CV death in Class II, and similarly, glucose to death from other causes. CONCLUSION: Addressing cohort heterogeneity in relation to BC survival is important in understanding the relationship between metabolic markers and cause-specific death in presence of competing outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1928-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4650114
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46501142015-11-19 Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis Wulaningsih, Wahyu Vahdaninia, Mariam Rowley, Mark Holmberg, Lars Garmo, Hans Malmstrom, Håkan Lambe, Mats Hammar, Niklas Walldius, Göran Jungner, Ingmar Coolen, Anthonius C. Van Hemelrijck, Mieke BMC Cancer Research Article BACKGROUND: Abnormal glucose and lipids levels may impact survival after breast cancer (BC) diagnosis, but their association to other causes of mortality such as cardiovascular (CV) disease may result in a competing risk problem. METHODS: We assessed serum glucose, triglycerides (TG) and total cholesterol (TC) measured prospectively 3 months to 3 years before diagnosis in 1798 Swedish women diagnosed with any type of BC between 1985 and 1999. In addition to using Cox regression, we employed latent class proportional hazards models to capture any heterogeneity of associations between these markers and BC death. The latter method was extended to include the primary outcome (BC death) and competing outcomes (CV death and death from other causes), allowing latent class-specific hazard estimation for cause-specific deaths. RESULTS: A lack of association between prediagnostic glucose, TG or TC with BC death was observed with Cox regression. With latent class proportional hazards model, two latent classes (Class I and II) were suggested. Class I, comprising the majority (81.5 %) of BC patients, had an increased risk of BC death following higher TG levels (HR: 1.87, 95 % CI: 1.01–3.45 for every log TG increase). Lower overall survival was observed in Class II, but no association for BC death was found. On the other hand, TC positively corresponded to CV death in Class II, and similarly, glucose to death from other causes. CONCLUSION: Addressing cohort heterogeneity in relation to BC survival is important in understanding the relationship between metabolic markers and cause-specific death in presence of competing outcomes. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1928-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-11-17 /pmc/articles/PMC4650114/ /pubmed/26577580 http://dx.doi.org/10.1186/s12885-015-1928-z Text en © Wulaningsih et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Wulaningsih, Wahyu
Vahdaninia, Mariam
Rowley, Mark
Holmberg, Lars
Garmo, Hans
Malmstrom, Håkan
Lambe, Mats
Hammar, Niklas
Walldius, Göran
Jungner, Ingmar
Coolen, Anthonius C.
Van Hemelrijck, Mieke
Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis
title Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis
title_full Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis
title_fullStr Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis
title_full_unstemmed Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis
title_short Prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis
title_sort prediagnostic serum glucose and lipids in relation to survival in breast cancer patients: a competing risk analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650114/
https://www.ncbi.nlm.nih.gov/pubmed/26577580
http://dx.doi.org/10.1186/s12885-015-1928-z
work_keys_str_mv AT wulaningsihwahyu prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT vahdaniniamariam prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT rowleymark prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT holmberglars prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT garmohans prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT malmstromhakan prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT lambemats prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT hammarniklas prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT walldiusgoran prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT jungneringmar prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT coolenanthoniusc prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis
AT vanhemelrijckmieke prediagnosticserumglucoseandlipidsinrelationtosurvivalinbreastcancerpatientsacompetingriskanalysis